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Abstract
Introduction: There are currently no established prognostic models for ‘low-gradient’ severe
aortic stenosis (AS); including those with low-flow, low-gradient (LFLG) or normal-flow,
low-gradient (NFLG) severe AS. The “Cardiac Damage Staging Classification” has been
validated as a clinically useful prognostic tool in high-gradient severe AS, but not yet in these
other common subtypes of severe AS, LFLG or NFLG.
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Methods: We analyzed data from the National Echocardiography Database of Australia, a
large national multicenter registry with individual data linkage to mortality. Of 192,060

re
-p
r

adults (aged 62.8±17.8 years) with comprehensive ultrasound profiling of the native aortic
valve studied between 2000-2019, 12,013 (6.3%) had severe AS. Based on standard

lP

echocardiographic parameters, we identified 5,601 high-gradient, 611 classical and 959
paradoxical LFLG and 911 NFLG severe AS patients. Mean follow-up was 88±45 months.

ur
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All-cause and cardiovascular-related mortality were assessed for each group on an adjusted
basis (age and sex) and analyzed by cardiac damage stage.

Jo

Results: LFLG patients had greater associated cardiac damage at diagnosis (Stages 3-4 in
34% Classical LFLG, 22.5% paradoxical LFLG, 15.5% NFLG and 14% high-gradient AS,
p<0.001). In all 4 major subtypes of severe AS, there was a progressive increase in 1- and 5year mortality with increasing cardiac damage score. For example, in paradoxical LFLG,
compared with stage 0 patients, adjusted 1-year all-cause mortality was 22% higher in Stage
1 patients, 55% higher in stage 2 (p=0.095) and 155% higher in stages 3-4 patients (p<0.001).
In classical LFLG patients, compared with stage 1 patients, adjusted 1-year all-cause
mortality was 55% higher in Stage 2 patients (p=0.018) and 100% higher in stages 3-4
patients (p<0.001).
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Conclusion: Regardless of severe AS subtype, increasing severity denoted by the cardiac
damage staging classification is strongly associated with increasing mortality risk.
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Introduction
A substantial subset of patients with evidence of severe aortic stenosis (AS) on
echocardiography (aortic valve area, AVA <1cm2) do not have high pressure gradients across
their aortic valve (i.e. mean gradient ≥40mmHg and/or peak velocity ≥4m/s). This
phenomenon is commonly termed “low-gradient” severe AS(1). Where this occurs due to
reduced left ventricular stroke volume, patients are said to have “low-flow low-gradient”
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f

(LFLG) severe AS. These cases can be further delineated according to concurrent reduced
(Classical LFLG) versus preserved left ventricular ejection fraction (Paradoxical LFLG).
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Patients with normal stroke volume are termed “normal-flow low-gradient” (NFLG); while
current guidelines generally regard these as having only moderate AS, it has been argued that
up to 50% have severe stenosis with evidence backing the case for early intervention (1).

lP

Currently, however, there are no established prognostic models specific to ‘low-gradient’

ur
na

patients, to help guide management decisions.

In predominantly high-flow, high-gradient severe AS patients scheduled for intervention,

Jo

Généreux and colleagues recently described a novel prognostic model, using a staging
classification system based on the extent of extra aortic valve (AV) anatomical and functional
cardiac damage on echocardiography(2). This cardiac damage staging classification has been
more recently validated in larger cohorts of both symptomatic and asymptomatic severe AS
patients(3,4), but only a small minority of patients in these studies had LFLG severe AS (less
than 20%).
In this context, the aim of our study was to explore the prognostic utility of this cardiac
damage classification, specifically in ‘low-gradient’ patients, by analyzing data from the
National Echo Database of Australia (NEDA)(5). NEDA is a large clinical registry currently
containing over 1 million echocardiograms, in more than 600,000 unique individuals, and has
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already generated clinically important insights into the prevalence and outcomes of aortic
stenosis(6,7).

Methods
Study Design and Data

oo
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The purpose and overall design of the large, multicenter clinical registry NEDA have been
previously described(5). In brief, NEDA is an ongoing observational registry containing
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detailed echocardiographic and basic demographic data of adults from over 25 participating
centers around Australia. At the time of study census, the NEDA database contained more

lP

than one million echo reports from more than 600,000 individual patients. Survival status and
date of death (when relevant) for each patient in the database was obtained at the study

ur
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census date (May 2019) using enhanced probability matching linkage with the well-validated
Australian National Death Index(8). Causes of death were categorized according to the

Jo

International Classification of Diseases-10th Revision (ICD-10) coding(9). Events with ICD10 chapter codes in the range of I00 to I99 were considered as cardiovascular-related
mortality; these include valvular heart disease, ischemic heart disease, heart failure,
cerebrovascular disease and peripheral vascular disease.
Study Cohort
From the entire NEDA database at time of study census (May 2019), only patients ≥18 years
with echocardiographic investigations performed since the year 2000 and containing
parameters necessary for the appropriate diagnosis of severe AS were included in this
analysis. Hence, only echocardiographic investigations with available AV Area (AVA), AV
peak velocity and AV mean gradient data were included. Additionally, for patients with
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multiple available serial echocardiographic studies, only the first chronological investigation
was included. This resulted in an analysis cohort of 199,543 patients that was then further
assessed to specifically identify patients with severe native valve AS (Figure 1).
Patients were classified into the different subtypes of severe AS using criteria based on
current expert recommendations(1,10). High-gradient severe AS defined as AV mean gradient
≥40mmHg and/or peak velocity ≥4m/s (regardless of AVA). Classical LFLG severe AS
defined as AVA≤1cm2 with AV mean gradient <40mmHg, AV peak velocity <4m/s, Stroke
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Volume Index (SVI) ≤35ml/m2 and Left Ventricular Ejection Fraction (LVEF) <50%.
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Paradoxical LFLG severe AS defined as AVA ≤1cm2 with AV mean gradient <40mmHg, AV
peak velocity <4m/s, SVI ≤35ml/m2 and LVEF ≥50%. NFLG severe AS defined as

lP

AVA≤1cm2 with AV mean gradient <40mmHg, AV peak velocity <4m/s and SVI >35ml/m2.
AVA for all included echocardiograms was calculated from the continuity equation using

ur
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either the Velocity Time Integral (VTI) and/or peak velocity ratio(11), with the minimum
value used for above diagnostic criteria. Reported LVEF was obtained by following

Jo

hierarchal methods: physician reported, volumetric apical biplane (Simpson’s), volumetric
apical four-chamber, volumetric apical two-chamber, Teichholz formula. LV mass was
calculated using the American Society of Echocardiography (ASE) 2D linear formula(12).
Patients were recorded to have undergone AVR during follow-up if any of their subsequent
available echocardiograms in the database reported evidence of a replaced or implanted aortic
valve. The follow-up period for each patient was from time of the diagnostic echocardiogram
to time of study census (May 2019, as above). Mean follow-up was 95 (±45) months for
high-gradient patients, 76 (±43) months for classical LFLG patients, 66 (±39) months for
paradoxical LFLG patients and 83 (±45) months for NFLG patients (p<0.001).
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Cardiac Damage Staging Classification
Patients were categorized into five independent stages based on the degree of cardiac damage
reported during index echocardiogram (i.e. first diagnostic TTE for severe AS), as previously
defined(2,4):
Stage 0 – No significant extra AV damage detected.
Stage 1 – evidence of left ventricular (LV) damage including hypertrophy (LV mass index

oo
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>95g/m2 for women, >115g/m2 for men), systolic dysfunction (LVEF <50%) and/or severe

re
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diastolic dysfunction (E/e’ >14).

Stage 2 – evidence of left atrium (LA) or mitral valve (MV) damage including LA dilatation

regurgitation (MR).

lP

(>34mL/m2), Atrial Fibrillation (recorded at time of echo) and/or moderate-severe mitral

ur
na

Stage 3 – evidence of systolic pulmonary hypertension (right ventricular systolic pressure
[RVSP] ≥60mgHg) and/or moderate-severe tricuspid regurgitation (TR).

Jo

Stage 4 – evidence of moderate-severe right ventricular (RV) systolic dysfunction.
Statistical Analysis

Statistical calculations were performed using SPSS software (IBM, Armonk, New York) and
significance was inferred at a 2-sided p value of <0.05. Comparisons between severe AS
groups were assessed by ANOVA, student’s t-test or chi-square test, as appropriate.
Differences in all-cause and cardiovascular-related 1- and 5-year mortality between cardiac
damage stages for each severe AS subgroup were plotted (Kaplan-Meir survival curves) and
further assessed with Cox multivariable regression analyses, adjusting for patient age and sex.
Patients with stages 3 and 4 were grouped together in mortality curves and regression
analyses (due to the low number of stage 4 patients). For all-cause mortality analyses,
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patients were only included if follow-up was at least 1 year or 5 years, for each relevant
analysis. Additionally, for cardiovascular-related mortality analyses, patients were only
included if the cause of death was available. We also performed a ‘sensitivity’ analysis,
repeating the above calculations only in patients without recorded AVR during follow-up (see
Supplemental Table 1).

oo
f

Results
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Of 199,543 patients with comprehensive echocardiographic assessment of their AV (Figure
1), 192,060 had a native AV (mean age 62.8±17.8 years and 53% were men). Severe AS was
identified in 12,013 patients (6.3%, 95% CI 6.2-6.4%). Of these, 5,601 patients had high-

lP

gradient severe AS and 6,412 patients had low-gradient severe AS, 2,741 of which having

ur
na

SVI data available. The final studied cohort included 5,601 patients with high-gradient severe
AS, 611 patients with confirmed classical LFLG severe AS, 959 patients with confirmed

Jo

paradoxical LFLG severe AS and 991 patients with confirmed NFLG severe AS (Table 1).
The distribution of Cardiac Damage Stage among the different subtypes of severe AS is
shown in Figure 2. Patients with classical LFLG presented with higher cardiac damage
scores (mean score 2.1±0.8) compared with other severe AS subtypes; mean score 1.4±1.2 in
paradoxical LFLG, 1.5±1.1 in NFLG patients and 1.4±1.1 in high-gradient patients
(p<0.001).
Survival data for all the 4 major subtypes of severe AS, by cardiac damage score, are shown
in Table 2 and Figures 3-6 below. Outcomes in the specific AS subtypes are summarized
below.
Cardiac Damage Stage and Outcomes in LFLG Patients
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No patients with classical LFLG were classified as Stage 0 due to the presence of LV systolic
impairment. In classical LFLG (Figure 3 & Supplemental Figure S1), compared to patients
with Stage 1, patients with Stages 3/4 had significantly higher all-cause and cardiovascular
adjusted mortality at both 1- and 5-years (p<0.001). Patients with Stage 2 had significantly
higher all-cause adjusted mortality at both 1- and 5-years (p=0.018 and p=0.036) but nonsignificantly higher cardiovascular adjusted mortality (p=0.075 and p=0.155).
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In paradoxical LFLG (Figure 4 & Supplemental Figure S2), compared to patients with Stage
0, patients with Stages 3/4 had significantly higher all-cause and cardiovascular adjusted
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mortality at both 1- and 5-years (p<0.003), while patients with Stage 2 had significantly
higher cardiovascular 1-year adjusted mortality (p=0.028) and both all-cause and
cardiovascular 5-year adjusted mortality (p=0.002 and p=0.001) but only non-significantly

lP

higher

all-cause

ur
na

1-year adjusted mortality (p=0.095). There was no significant difference in any adjusted
mortality between patients with Stage 0 and Stage 1.

Jo

Cardiac Damage Stage and Outcomes in NFLG Patients
In severe NFLG AS (Figure 5 & Supplemental Figure S3), compared to Stage 0 patients,
those with Stages 3/4 had significantly higher all-cause and cardiovascular adjusted mortality
at both 1- and 5-years (p<0.013 and p<0.001), while in Stage 2 patients only adjusted
cardiovascular mortality was significantly higher at both 1- and 5-years (p=0.033 and
p=0.001). 5-year adjusted cardiovascular mortality was significantly higher in Stage 1 than
Stage 0 patients (p=0.009). Both adjusted all-cause and cardiovascular mortality was similar
between Stage 1 and Stage 2 patients.
Cardiac Damage Stage and Outcomes in High-Gradient Patients
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High-gradient severe AS patients with Stages 3/4 had substantially higher mortality
(p<0.006) at both 1- and 5-years compared to those with Stage 0 (Figure 6 & Supplemental
Figure S4). For Stage 2 patients, 5-year all-cause and cardiovascular mortality was also
significant higher (p<0.005). Unexpectedly, 1-year outcomes were significantly higher in
Stage 1 (p=0.014 and p=0.026), but not in Stage 2 patients (p=0.117 and p=0.061). There was
no significant separation between those with Stages 1 and Stage 2 for any of the above
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analyses.
Cardiac Damage Stage and Outcomes in patients without recorded AVR
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Repeating the above analyses including only patients without recorded AVR during the
follow-up period (see Supplemental Figures S5-S12) revealed similar results. In classical

lP

LFLG patients, there was stronger statistical separation between Stage groups; the previously
non-significant higher cardiovascular mortality rates between Stage 2 and Stage 1 patients

ur
na

were significant in this analysis (p=0.017 and p=0.031, at 1- and 5-years, respectively).
Likewise, in high-gradient patients, the greater adjusted 5-year mortality in Stage 1 patients

Jo

and 1-year mortality in Stage 2 patients became statistically significantly (p<0.001).

Discussion
In this study of a large contemporary “real-world” cohort, of over 2,500 patients with severe
‘low-gradient’ AS and detailed echocardiographic assessment, we present for the first time
the prognostic implications of the extent of cardiac damage at time of diagnosis in this
relatively poorly characterized subpopulation of AS patients. We found a significant and
strong association between cardiac damage stage and medium to long-term survival in
classical LFLG, paradoxical LFLG and NFLG patients. Our results further contribute to the
evolving understanding of low-gradient severe AS and validate the recently described
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Cardiac Damage Staging Classification as a clinically relevant prognostic tool to help guide
management decisions in such patients.
LFLG AS is characterized by evidence of severe stenosis (AVA ≤1cm2) with reduced flow
across the aortic valve (SVI ≤35ml/m2). This heterogenous group is then often further
subdivided according the underlying cause of the reduced cardiac output as distinguished by
ventricular contractility; patients with reduced left ventricular systolic function are said to
have classical LFLG and patients with preserved systolic function are deemed as
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“paradoxical“ LFLG. In this latter group, the associated reduced flow state is due to

re
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restrictive left ventricular pathophysiology and/or small ventricular volumes, and this
situation is often compared to heart failure with preserved ejection fraction(1).

lP

Généreux and colleagues first suggested a cardiac damage related staging classification(2) and
demonstrated a strong prognostic association between the extent of extra-AV cardiac damage

ur
na

and 1-year outcomes in 1,611 severe AS patients undergoing AVR. More recently, this
prognostic association was also demonstrated for long-term outcomes in a non-selected

Jo

severe AS cohort(4). However, in this series the majority of patients (77%) underwent AVR
and only a minority (19%; 224 patients) had LFLG AS. Considering that patients with LFLG
severe AS are known to have poorer outcomes(1), both in general and following AVR,
compared to high-gradient severe AS patients, it is clearly important to investigate and
identify valid and reliable prognostic markers in LFLG AS patients – as we have done here.
Subjects with classical LFLG AS have evidence of associated LV systolic dysfunction and
thus, by definition, cannot be classified as Stage 0. We observed a significant incremental
mortality increase with each cardiac damage stage in classical LFLG patients, including
following adjustment for age and sex. Adjusted 1- and 5-year mortality was 56% and 20%
higher, respectively, in those with evidence of significant LA and/or MV disease (Stage 2) at
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diagnosis and 100% (i.e. 2-fold) and 38% higher, respectively, in those with evidence of
significant pulmonary hypertension, tricuspid and/or RV disease (Stages 3/4) at diagnosis.
This observed prognostic association between cardiac damage staging and medium to longterm outcomes became even more pronounced when including only classical LFLG patients
with no known AVR during follow-up (Supplemental Figures S5-6).
Compared to classical LFLG patients, those with paradoxical LFLG had less cardiac damage
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at diagnosis, manifested by significantly lower rates of Stages 2-4. In paradoxical LFLG
patients, following adjustment, there was no significant difference in outcomes for those with
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the previously specified criteria for LV hypertrophy or diastolic failure (i.e. in Stage 1 vs.
Stage 0 patients). This is not surprising as the presence of low SVI despite the ‘normal’ LV
systolic function in this population implies an underlying element of LV ‘insufficiency’. On

lP

the other hand, as with classical LFLG, we observed an incremental mortality rise with higher

ur
na

cardiac damage stages in paradoxical LFLG patients. Adjusted mortality at 1- and 5-years
was 56% and 38% higher, respectively, in those with evidence of significant LA and/or MV

Jo

disease (Stage 2) at diagnosis and 156% and 64% higher, respectively, in those with evidence
of significant pulmonary hypertension, tricuspid and/or RV disease (Stages 3/4) at diagnosis.
Again, these associations remained significant, when considering only paradoxical LFLG
patients with no known AVR during follow-up (Supplemental Figures S7-8).
The management of NFLG severe AS patients can often be challenging; while current
guidelines(10,13) regard these as having only moderate AS, evidence suggests intervention is
indicated at least in some(14). In this context, it is pertinent to highlight that the accepted AVA
cut-off for severe stenosis of 1cm2 corresponds in many patients to a mean gradient of only
30-35mmHg(15) and that this AVA threshold (1cm2) has been independently associated with
improved outcomes following intervention(16). As with LFLG patients, we observed a
significant association between cardiac damage stage and survival in NFLG patients.
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However, this correlation was more prominent with cardiovascular-specific mortality;
adjusted all-cause mortality in NFLG Stage 1 and Stage 2 patients was not significantly
higher, but 5-year adjusted cardiovascular mortality was 96% and 107% higher, respectively.
The relative prognosis of Stage 4 NFLG patients (vs. Stage 0) was substantially worse, with
275% and 55% higher 1- and 5-year adjusted all-cause mortality, respectively.
Only a minority of low-gradient patients had a documented AVR (either surgical or
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transcatheter) during the follow-up period; 19.5% of classical LFLG patients, 13.2% of
paradoxical LFLG patients and 27.5% of NFLG patients. These figures must be interpreted
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with caution, however, as they would likely underestimate the true incidence of AVR
performed by not accounting for patients without post-procedure TTE recorded in the
database (due to early post-operative mortality or loss to follow-up, for example).

lP

Nevertheless, our supplemental analysis demonstrates, for the first time, the prognostic power

ur
na

of this echocardiographic cardiac damage staging classification in a severe AS cohort
undergoing mainly conservative management.

Jo

Consistent with previously reported data(4), LFLG patients in our cohort presented with more
advanced cardiac damage staging compared to high-gradient patients; overall, the relative
percentage of Stage 3/4 in LFLG severe AS was 27% compared with 14% in high-gradient
severe AS. Our results again confirm the prognostic utility of the cardiac damage staging
classification in a large cohort of 5,601 unselected high-gradient severe AS patients,
including specifically a sub-cohort of over 3,000 patients with no recorded valvular
intervention (see Supplemental Materials). Compared to patients with no evidence of extraAV cardiac damage, adjusted all-cause mortality was significantly higher in patients with
Stages 1-2 and higher still in those with Stage 3/4 in the classification. Interestingly, there
was only negligible difference in adjusted outcomes between Stage 1 and 2 patients (i.e. no
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adverse prognostic association seen with the presence of severe MR or LA disease in those
with evidence of LV diastolic or systolic dysfunction).
Limitations
NEDA represents a national network of over 25 participating centers with both inpatient and
outpatient services across all the states of Australia. Therefore, it represents the heterogeneity
of cases seen in ‘real-world’ clinical cardiology practice across an advanced healthcare

oo
f

system servicing a multi-racial population. Inherently, NEDA contains a certain selection
bias by drawing on results only from those adults undergoing cardiac ultrasound.

re
-p
r

Nevertheless, Australia’s universal health-care system minimizes the chance of important
referral bias based on subjects’ ability to pay for this test (or for subsequent interventions).

lP

NEDA does not contain routine clinical data and we acknowledge the importance of
symptomatic status and comorbidities in the prognostication and appropriate management of

ur
na

severe AS patients. Nonetheless, we believe that over-reliance on symptomatology in the
natural history of severe AS may be detrimental, considering that many patients do not

Jo

present with overt symptoms due to progressively adopting a more sedentary lifestyle and
especially with recent evidence showing benefit of early intervention compared to an initial
conservative approach in asymptomatic severe AS patients(17,18). Indeed, current guidelines
highlight the diagnostic and prognostic benefit of exercise testing and other imaging
modalities in presumed asymptomatic patients with severe AS(13).
SVI measurement was available in slightly less than half the patients in the database with a
low-gradient severe AS profile, which may have introduced a selection bias into the final
analyzed cohort. The frequency of SVI measurement in the low-gradient group increased
from 43% overall to 73% considering only patients diagnosed from 2015 (data not shown in
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results) – suggesting that awareness in routine clinical practice for the different hemodynamic
profiles of severe AS may have improved over the study period.
Several echo parameters used for the staging classification, such as MR and TR severity or
estimated pulmonary systolic pressure, are known to be dynamic and depend on each
patient’s fluid status (for example) at time of index TTE. This limitation (in context of the
cardiac damage classification) has not been described previously and should be considered
when assessing patients with severe congestive cardiac failure. There was no available
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objective raw data for right ventricular systolic function (i.e. TAPSE or RV S’) in the
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database and the presence or absence of RV dysfunction was therefore determined based on
the reporting cardiologist qualitative assessment. This may account for the smaller proportion
of Stage 4 patients in our cohort, compared to previous reports(2,4) (1.8% vs. 9-12%). Also,

lP

we acknowledge sources of echo-related measurement error, especially those related to LV

ur
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outflow tract diameter assessment(19); this may be particularly relevant to subjects diagnosed

Jo

with low-gradient severe AS.

Conclusion

The extent of echocardiographic extra-AV cardiac damage at diagnosis, as described by the
Cardiac Damage Stage Classification, is significantly and independently associated with
medium and long-term outcomes in low-gradient severe AS sub-populations. We believe that
our novel data supports the use of this simple yet powerful prognostic tool and will assist
clinicians with management decisions in the major recognized subtypes of severe AS
patients.
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Figure Legends
Figure 1 – Study Flowchart
Figure 2 – Cardiac Damage Stage Distribution
Showing the observed distribution of Cardiac Damage Stages between the different subtypes
of severe AS

oo
f

Figure 3 – 5-year mortality in classical LFLG severe AS
Showing 5-year all-cause and cardiovascular-related mortality rates in classical LFLG

re
-p
r

patients, both unadjusted (Left) and adjusted for patient age and sex (Right), according to
cardiac damage stage [p values comparing to Stage 1 group].

lP

Figure 4 – 5-year mortality in paradoxical LFLG severe AS

ur
na

Showing 5-year all-cause and cardiovascular-related mortality rates in paradoxical LFLG
patients, both unadjusted (Left) and adjusted for patient age and sex (Right), according to

Jo

cardiac damage stage [p values comparing to Stage 0 group].
Figure 5 – 5-year mortality in NFLG severe AS
Showing 5-year all-cause and cardiovascular-related mortality rates in NFLG patients, both
unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac damage
stage [p values comparing to Stage 0 group].
Figure 6 – 5-year mortality in high-gradient severe AS
Showing 5-year all-cause and cardiovascular-related mortality rates in high-gradient patients,
both unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac
damage stage [p values comparing to Stage 0 group].
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Tables
Table 1 – Baseline Group Characteristics and Cardiac Damage Stage Parameters
Classical LFLG

Paradoxical LFLG

NFLG

(n=5601)

(n=611)

(n=959)

(n=991)

Mean Age (±SD)

75.0 (±13.0)

76.2 (±12.2)

74.3 (±14.4)

77.2 (±12.0)

<0.001

Female Sex

2392 (42.7%)

222 (36.3%)

602 (62.8%)

578 (58.3%)

<0.001

27.8 (±6.1)

26.9 (±5.7)

28.6 (±6.9)

26.2 (±5.2)

<0.001

2300 (41.1%)

119 (19.5%)

126 (13.2%)

273 (27.5%)

<0.001

AVA (VTI) (cm2)

0.80 (±0.28)

0.83 (±0.28)

0.94 (±0.17)

<0.001

Index AVA (VTI) (cm2/m2)

0.43 (±0.15)

Mean Gradient (mmHg)

49.8 (±12.4)

Mean BMI (±SD)
AVR during follow-up

4.6 (±0.5)

Cardiac Damage Stage

1695 (30.3%)

ur
na

Stage 0
Stage 1

975 (17.4%)

High LV Mass

E/e' >14

Stage 2

Moderate-severe MR
Atrial Fibrillation

Stage 3/4

<0.001

19.2 (±9.7)

18.0 (±9.6)

27.6 (±7.1)

<0.001

2.8 (±0.7)

2.7 (±0.7)

3.4 (±0.4)

<0.001

0 (0%)

328 (34.2%)

259 (26.1%)

<0.001

148 (24.2%)

161 (16.8%)

171 (17.3%)

<0.001

254 (26.5%)

316 (31.9%)

835 (14.9%)

611 (100%)

0 (0%)

163 (16.5%)

133 (21.8%)

178 (18.6%)

264 (26.6%)

2134 (38.1%)

LA dilatation (>34ml/m )

0.54 (±0.12)

287 (47.0%)

1286 (25.4%)

2

0.48 (±0.15)

1763 (31.5%)

Jo

LVEF <50%

256 (41.9%)

256 (26.7%)

406 (41.0%)

2233 (39.9%)

283 (46.3%)

285 (29.7%)

419 (42.3%)

763 (13.6%)

200 (32.7%)

111 (11.6%)

178 (18.0%)

524 (9.4%)

125 (20.5%)

183 (19.1%)

96 (9.7%)

797 (14.2%)

p value

0.45 (±0.16)

lP

Peak Velocity (m/s)

0.87 (±0.26)

re
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r

Aortic Valve Characteristics

oo
f

High Gradient

Variable

207 (33.9%)

214 (22.3%)

155 (15.6%)

Moderate-severe TR

447 (8.0%)

161 (26.4%)

174 (18.1%)

110 (11.1%)

RVSP≥60 (mmHg)

473 (8.4%)

77 (12.6%)

75 (7.8%)

70 (7.1%)

RV systolic impairment

113 (2.0%)

25 (4.1%)

11 (1.1%)

8 (0.8%)

Note: Patients were classified into the highest hierarchical stage (i.e. worst stage) if at least one of the
criteria was met within that stage.
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Table 2 – 1- and 5-year mortality according to severe AS subtype and Cardiac Damage Stage
1-year All-Cause Mortality
High Gradient

Classical LFLG

Paradoxical LFLG

NFLG

(n=5542)

(n=590)

(n=900)

(n=969)

Stage 0

10.7% [ref]

N/A

8.2% [ref]

7.9% [ref]

Stage 1

14.3% [1.32±1.06-1.65]

19.2% [ref]

13.5% [1.27±0.71-2.28]

5.3% [0.56±0.26-1.24]

Stage 2

14.8% [1.16±0.96-1.40]

31.1% [1.69±1.09-2.61]

18.1% [1.54±0.93-2.55]

12.3% [1.16±0.65-1.95]

Stages 3/4

31.4% [2.35±1.93-2.87]

38.0% [2.22±1.44-3.43]

31.5% [2.79±1.72-4.54]

22.8% [2.07±1.18-3.62]

High Gradient

Classical LFLG

Paradoxical LFLG

NFLG

(n=5201)

(n=550)

oo
f

1-year Cardiovascular Mortality
(n=893)

6.4% [ref]

N/A

2.0% [ref]

1.7% [ref]

Stage 1

9.2% [1.39±1.04-1.85]

12.4% [ref]

3.5% [1.21±0.37-4.00]

2.5% [1.22±0.31-4.89]

Stage 2

9.9% [1.26±0.99-1.60]

19.9% [1.66±0.95-2.90]

9.5% [2.82±1.12-7.11]

7.7% [3.13±1.09-8.96]

Stages 3/4

23.4% [2.71±2.11-3.48]

28.3% [2.48±1.43-4.28]

14.7% [4.23±1.68-10.6]

12.9% [5.07±1.60-15.3]

re
-p
r

Stage 0

(n=834)

5-year All-Cause Mortality
(n=4579)
38.8% [red]

Stage 1

44.0% [1.13±0.99-1.29]

Stage 2
Stages 3/4

Paradoxical LFLG

NFLG

(n=465)

(n=631)

(n=746)

N/A

39.6% [ref]

39.6% [ref]

62.1% [ref]

53.2% [1.09±0.77-1.54]

49.6% [1.19±0.86-1.66]

51.0% [1.17±1.05-1.30]

71.7% [1.37±1.03-1.82]

67.1% [1.63±1.21-2.19]

56.1% [1.27±0.97-1.67]

72.6% [1.85±1.64-2.10]

82.3% [1.97±1.47-2.63]

76.7% [2.21±1.64-2.98]

72.9% [1.94±1.43-2.64]

Jo

ur
na

Stage 0

Classical LFLG

lP

High Gradient

5-year Cardiovascular Mortality

High Gradient

Classical LFLG

Paradoxical LFLG

NFLG

(n=4112)

(n=394)

(n=512)

(n=630)

Stage 0

20.1% [ref]

Stage 1

26.8% [1.30±1.08-1.57]

Stage 2
Stages 3/4

N/A

13.1% [ref]

12.4% [ref]

38.0% [ref]

23.8% [1.21±0.65-2.23]

28.6% [2.09±1.20-3.62]

29.6% [1.27±1.09-1.48]

44.8% [1.35±0.91-1.99]

37.4% [2.42±1.46-4.02]

33.9% [2.24±1.39-3.62]

50.3% [2.25±1.90-2.66]

54.5% [1.87±1.26-2.78]

44.6% [3.18±1.90-5.34]

37.8% [2.84±1.65-4.87]

Table showing the unadjusted 1- and 5-year all-cause and cardiovascular mortality rates and
also the fully adjusted [HR ± 95% CI]. (n) denotes number at risk at start of each analysis.

Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06,
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

oo
f
re
-p
r
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06,
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

f
oo
-p
r
re
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

f
oo
-p
r
re
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

f
oo
-p
r
re
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

f
oo
-p
r
re
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

f
oo
-p
r
re
lP
ur
na
Jo
Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Highlights
Prognosis in low-gradient severe AS is worse with greater cardiac damage score



Cardiac Damage Staging score is useful for prognosis in low-gradient severe AS



Low versus high gradient severe AS cases generally have higher cardiac damage scores
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Supplemental Materials

Supplementary Analysis: Repeating the main analysis, including only patients without
recorded AVR during follow-up.
Supplemental Table 1 – Baseline Group Characteristics
High Gradient

Classical LFLG

Paradoxical LFLG

NFLG

(n=3298)

(n=491)

(n=829)

(n=718)

Mean Age (±SD)

77.2 (±12.8)

77.7 (±11.5)

74.5 (±14.8)

78.1 (±12.4)

Female Sex

1483 (45.0%)

192 (39.1%)

535 (64.5%)

445 (62.0%)

27.0 (±6.0)

26.6 (±5.6)

28.4 (±6.8)

25.8 (±5.4)

AVA from VTI (cm2)

0.79 (±0.32)

0.85 (±0.30)

0.87 (±0.27)

0.94 (±0.18)

Mean Gradient (mmHg)

48.5 (±12.1)

17.5 (±9.5)

16.9 (±9.3)

26.4 (±7.3)

4.5 (±0.5)

2.7 (±0.7)

2.6 (±0.7)

3.3 (±0.5)

Stage 0

1079 (32.7%)

0 (0%)

290 (35.0%)

189 (26.3%)

Stage 1

549 (16.6%)

120 (24.4%)

146 (17.6%)

129 (18.0%)

Variable

Mean BMI (±SD)

Aortic Valve Characteristics

Peak Velocity (m/s)

Cardiac Damage Stage

High LV Mass

1018 (30.9%)

244 (49.7%)

223 (26.9%)

235 (32.7%)

LVEF <50%

495 (15.0%)

491 (100%)

0 (0%)

112 (15.6%)

E/e' >14

674 (20.4%)

103 (21.0%)

149 (18.0%)

186 (25.9%)

Stage 2

1118 (33.9%)
2

LA dilatation (>34ml/m )

195 (39.7%)

208 (25.1%)

268 (37.3%)

1214 (36.8%)

219 (44.6%)

230 (27.7%)

290 (40.4%)

Moderate-severe MR

415 (12.6%)

166 (33.8%)

91 (11.0%)

121 (16.9%)

Atrial Fibrillation

345 (10.5%)

108 (22.0%)

155 (18.7%)

75 (10.4%)

Stage 3/4

552 (16.7%)

176 (35.8%)

185 (22.3%)

132 (18.4%)

Moderate-severe TR

303 (9.2%)

140 (28.5%)

149 (18.0%)

93 (13.0%)

RVSP≥60 (mmHg)

344 (10.4%)

64 (13.0%)

68 (8.2%)

62 (8.6%)

89 (2.7%)

20 (4.1%)

7 (0.8%)

6 (0.8%)

RV systolic impairment
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Supplemental Figures

Supplemental Figure S1 – 1-year survival in classical LFLG severe AS
Showing 1-year mortality rates in classical LFLG patients, both unadjusted (Left) and adjusted
for patient age and sex (Right), according to cardiac damage stage [p values comparing to Stage
1 group].
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Supplemental Figure S2 – 1-year survival in paradoxical LFLG severe AS
Showing 1-year mortality rates in paradoxical LFLG patients, both unadjusted (Left) and
adjusted for patient age and sex (Right), according to cardiac damage stage [p values comparing
to Stage 0 group].
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Supplemental Figure S3 – 1-year survival in NFLG severe AS
Showing 1-year mortality rates in NFLG patients, both unadjusted (Left) and adjusted for patient
age and sex (Right), according to cardiac damage stage [p values comparing to Stage 0 group].
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Supplemental Figure S4 – 1-year survival in high-gradient severe AS
Showing 1-year mortality rates in high-gradient patients, both unadjusted (Left) and adjusted for
patient age and sex (Right), according to cardiac damage stage [p values comparing to Stage 0
group].
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Supplemental Figure S5 – 1-year survival in classical LFLG severe AS without recorded AVR
Showing 1-year mortality rates in classical LFLG patients without recorded AVR, both
unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac damage stage
[p values comparing to Stage 1 group].

p<0.001

p=0.002

p=0.001

p=0.005

p=0.001

p=0.003
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Supplemental Figure S6 – 5-year survival in Classical LFLG without recorded AVR
Showing 5-year mortality rates in classical LFLG patients without recorded AVR, both
unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac damage stage
[p values comparing to Stage 1 group].

p<0.001

p<0.001

p=0.007

p=0.014

p=0.005
p=0.003
p=0.029
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p=0.031

Supplemental Figure S7 – 1-year survival in paradoxical LFLG severe AS without recorded
AVR
Showing 1-year mortality rates in paradoxical LFLG patients without recorded AVR, both
unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac damage stage
[p values comparing to Stage 0 group].

p<0.001
p<0.001
x
p=0.001
p=0.109

p=0.063

p=0.431

p<0.001
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Supplemental Figure S8 – 5-year survival in paradoxical LFLG without recorded AVR
Showing 5-year mortality rates in paradoxical LFLG patients without recorded AVR, both
unadjusted (Left) and adjusted for patient age and sex (Right), according to cardiac damage stage
[p values comparing to Stage 0 group].

p<0.001

p<0.001
p<0.001

p<0.001
p=0.279
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p<0.001
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Supplemental Figure S9 – 1-year survival in NFLG severe AS without recorded AVR
Showing 1-year mortality rates in NFLG patients without recorded AVR, both unadjusted (Left)
and adjusted for patient age and sex (Right), according to cardiac damage stage [p values
comparing to Stage 0 group].

p<0.001

p=0.017

p=0.339

p=0.011
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p=0.733

Supplemental Figure S10 – 5-year survival in NFLG severe AS without recorded AVR
Showing 5-year mortality rates in NFLG patients without recorded AVR, both unadjusted (Left)
and adjusted for patient age and sex (Right), according to cardiac damage stage [p values
comparing to Stage 0 group].
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Supplemental Figure S11 – 1-year survival in high-gradient severe AS without recorded AVR
Showing 1-year mortality rates in high-gradient patients without recorded AVR, both unadjusted
(Left) and adjusted for patient age and sex (Right), according to cardiac damage stage [p values
comparing to Stage 0 group].
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Supplemental Figure S12 – 5-year survival in high-gradient severe AS without recorded AVR
Showing 5-year mortality rates in high-gradient patients without recorded AVR, both unadjusted
(Left) and adjusted for patient age and sex (Right), according to cardiac damage stage [p values
comparing to Stage 0 group].

p<0.001
p<0.001
p<0.001

p<0.001

p<0.001
p<0.001

p<0.001
p<0.001
p<0.001
p<0.001
p<0.001

Downloaded for Anonymous User (n/a) at Macquarie University from ClinicalKey.com.au by Elsevier on June 06,
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

p<0.001

